We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

104 hedge funds and large institutions have $147M invested in Enzo Biochem, Inc. in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

591% more call options, than puts

Call options by funds: $663K | Put options by funds: $96K

47% more capital invested

Capital invested by funds: $100M → $147M (+$47.2M)

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

35% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 26

5% more funds holding

Funds holding: 99104 (+5)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
104
Holders Change
+5
Holders Change %
+5.05%
% of All Funds
2.77%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
23
Increased
35
Reduced
26
Closed
17
Calls
$663K
Puts
$96K
Net Calls
+$567K
Net Calls Change
+$386K
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
51
UBS Group
Switzerland
$275K -$891K -160,525 -78%
CCMH
52
Cornerstone Capital Management Holdings
New York
$272K +$115K +20,800 +84%
RJT
53
Raymond James Trust
Florida
$266K +$247K +44,500 New
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
$242K +$225K +40,600 New
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$233K +$216K +38,985 New
HCM
56
Highbridge Capital Management
New York
$231K +$215K +38,676 New
AIM
57
Acrospire Investment Management
Illinois
$221K -$129K -23,164 -39%
Walleye Trading
58
Walleye Trading
New York
$217K +$112K +20,100 +123%
Goldman Sachs
59
Goldman Sachs
New York
$205K -$772K -139,165 -80%
PP
60
PDT Partners
New York
$202K +$87.2K +15,720 +87%
MLICM
61
Metropolitan Life Insurance Company (MetLife)
New York
$194K +$181K +32,556 New
Jacobs Levy Equity Management
62
Jacobs Levy Equity Management
New Jersey
$184K +$16.1K +2,900 +10%
PPA
63
Parametric Portfolio Associates
Washington
$178K -$21.3K -3,844 -11%
Asset Management One
64
Asset Management One
Japan
$175K
LCM
65
Leisure Capital Management
California
$170K +$200 +36 +0.1%
NFA
66
Nationwide Fund Advisors
Ohio
$152K +$141K +25,417 New
EEG
67
E.E. Geduld
$149K
Neuberger Berman Group
68
Neuberger Berman Group
New York
$145K
AIG
69
American International Group
New York
$136K +$121K +21,846 +2,185%
VOYA Investment Management
70
VOYA Investment Management
Georgia
$134K +$124K +22,377 New
KBC Group
71
KBC Group
Belgium
$123K +$77K +13,875 +208%
BA
72
BlackRock Advisors
Delaware
$119K +$66.2K +11,921 +148%
CSS
73
Cubist Systematic Strategies
Connecticut
$111K +$103K +18,529 New
CS
74
Credit Suisse
Switzerland
$108K -$404K -72,876 -80%
PAM
75
Panagora Asset Management
Massachusetts
$105K -$79.8K -14,383 -45%

ENZ Hedge Fund Activity: Q2 2016 in Review

104 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q2 2016, worth a combined $147M — up 47% from $100M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ENZ positions and 17 closed out — a net gain of 6 holders — while 35 added to existing stakes and 26 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $5.23M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $4.2M.

  • 104 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q2 2016, up from 99 in Q1 2016.
  • Funds reported $147M of Enzo Biochem, Inc. stock for Q2 2016, up 47% quarter-over-quarter.
  • 23 funds opened new Enzo Biochem, Inc. positions in Q2 2016 and 17 closed out, a net change of +6 holders.
  • The largest Enzo Biochem, Inc. buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $5.23M added.
  • The largest Enzo Biochem, Inc. seller in Q2 2016 was Manulife (Manufacturers Life Insurance), an estimated $4.2M sold.

Based on aggregated 13F filings for Q2 2016.